C4 Therapeutics (CCCC) Stock: Buy, Sell, or Hold?
CCCC - C4 Therapeutics, Inc.
$3.14
-0.19 (-5.71%)
▼
5d:
+3.63%
30d:
-18.86%
90d:
-26.98%
HOLD
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When CCCC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CCCC shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: CCCC shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: CCCC is currently trading at $3.14, which is considered oversold relative to its 30-day fair value range of $3.18 to $3.88.
Technical Outlook: Technically, CCCC is in a strong uptrend. Immediate support is located at $2.88, while resistance sits at $3.48. Short-term momentum is weak, with the stock down 5.7% recently.
Market Sentiment: CCCC scores 89/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $13.33 (+324.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CCCC is in a strong uptrend. Immediate support is located at $2.88, while resistance sits at $3.48. Short-term momentum is weak, with the stock down 5.7% recently.
Market Sentiment: CCCC scores 89/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $13.33 (+324.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.18 -
$3.88
Company Quality Score
70/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
89.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (89/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.7%)
- BULLISH: Trading 324.6% below Wall St target ($13.33)
- CAUTION: Bottoming setup, but lagging the sector by 29% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$3.18 -
$3.88
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.88
Resistance Level
$3.48
Current Trend
Strong Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.15
Wall Street Target
$13.33
(+324.6%)
Revenue Growth (YoY)
2.8%
Profit Margin
-289.4%
Share & Embed Analysis
Last updated: October 02, 2026 2:26 AM ET
Data refreshes hourly during market hours. Next update: 3:26 AM
Data refreshes hourly during market hours. Next update: 3:26 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CCCC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$371 | 47 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 52 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 55 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$570 | 50 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$310 | 69 BUY |
